Institutional members access full text with Ovid®

Share this article on:

Persistence of Serum Bactericidal Antibody One Year After a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine Against Serogroup C Neisseria meningitidis Given to Adolescents Previously Immunized With a Glycoconjugate Vaccine

de Whalley, Philip C. S. MA*; Snape, Matthew D. MD*; Kelly, Dominic F. PhD*; Banner, Carly MSc*; Lewis, Susan BSc*; Diggle, Linda PhD*; John, Tessa M. MA*; Yu, Ly-Mee MSc; Omar, Omar MSc; Borkowski, Astrid PhD; Pollard, Andrew J. PhD*

The Pediatric Infectious Disease Journal: November 2011 - Volume 30 - Issue 11 - p e203-e208
doi: 10.1097/INF.0b013e318224fb14
Online-Only: Original Studies

Background: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. Adolescents are at particular risk from meningococcal disease, therefore they might benefit from a booster dose of vaccine. The duration of serologic response to such a booster in adolescents is unknown.

Methods: In a previous study, English schoolchildren, aged 9 to 12 years, who had received a monovalent MenC glycoconjugate vaccine in 1999–2000, were given either a plain polysaccharide vaccine (MenC-PS group, n = 150) or a glycoconjugate vaccine (MenC-CRM group, n = 95) at 13 to 15 years of age. In this follow-up study, serum bactericidal antibody titers and specific immunoglobulin G concentrations were assessed 1 year later. Results were compared with unboosted controls of similar age (control group, n = 298).

Results: Compliance with study protocol was achieved for 146 of the MenC-PS group, 92 of the MenC-CRM group, and 293 of the control group. Compared with the control group, both the MenC-PS and MenC-CRM groups had a significantly higher (P < 0.0001) geometric mean serum bactericidal antibody titers 1 year after the booster dose (geometric mean titers for MenC-PS group 3388 [95% confidence interval {CI}: 2460–4665]; MenC-CRM group 4417 [95% CI: 2951–6609]; control group 316 [95% CI: 252–396]). Specific immunoglobulin G concentration also rose and remained elevated 1 year after the booster.

Conclusions: A booster dose of MenC vaccine given to adolescents produced a marked rise in bactericidal antibody, which remained elevated 1 year later. Introduction of an adolescent booster of MenC vaccine might provide enhanced long-term population control of the disease.

From the *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom; †Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom; and ‡Novartis Vaccines, Marburg, Germany.

Accepted for publication May 10, 2011.

Supported by funds from Chiron (now Novartis) Vaccines. The Oxford Vaccine Group receives funding from the NIHR Oxford Partnership Comprehensive Biomedical Research Centre programme (including salary support for T.M.J. and M.D.S.).

A.J.P. has conducted clinical trials on behalf of Oxford University, sponsored by manufacturers of vaccines. A.J.P. does not accept personal payments from vaccine manufacturers; grants for support of educational activities are paid to an educational/administrative fund held by the Department of Paediatrics, University of Oxford. M.D.S. has received assistance to attend scientific meetings from Novartis Vaccines and Sanofi Pasteur and has spent a period of secondment at Novartis Vaccines (Sienna, Italy). D.F.K. has received assistance to attend scientific meetings from Wyeth and Novartis Vaccines. L.D. has received assistance to attend scientific meetings from Wyeth Pharmaceuticals and Sanofi Pasteur. T.M.J. has received assistance to attend scientific meetings from vaccine manufacturers, including Novartis vaccines. A.B. is an employee of Novartis Vaccines (Marburg, Germany).

The authors have no other funding or conflicts of interest to disclose.

Address for correspondence: Philip de Whalley, Clinical Research Fellow, Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, United Kingdom. E-mail:

© 2011 by Lippincott Williams & Wilkins, Inc.